Skip to content

Development and Validation of a Predictive Model for Cardiovascular Events in Patients with CKD Stage 5D

Development and Validation of a Predictive Model for Cardiovascular Events in Patients with CKD Stage 5D

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118693
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure

Interventions

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Stable dialysis more than 3 months 2.Age from 18 to 80 years 3.If they have cardiovascular diseases, they can receive standardized treatments such as antiplatelet therapy, ACEI/ARB, CCB, etc. 4.Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.An acute cardiovascular or cerebrovascular event occurred within 3 months during the screening period 2.Active infection 3. Patients in the active phase of liver disease with abnormal liver function (ALT or AST levels more than 2.5 times the upper limit of normal) or a history of liver cirrhosis 4.A history of cardiac surgery within 3 months prior to screening 5.Detection of malignant tumors within 3 months prior to screening, or undergoing radiotherapy/chemotherapy 6.A life-threatening severe infection occurred within 3 months prior to screening 7.Enrollment in other clinical research projects within 3 months prior to screening 8.Pregnant and lactating women, or patients using estrogen replacement therapy 9.Patients with active infectious diseases, such as active tuberculosis or HIV infection 10.Patients with psychiatric disorders who are taking psychotropic medications 11.The patient is deemed by the physician to be unlikely to follow up or to have poor compliance, and thus is not suitable for enrollment. 12. Patients who are unwilling to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiovascular Events;

Secondary

MeasureTime frame
soluble Suppression of Tumorigenicity 2,B-type Natriuretic Peptide change;All Cause Death;dialysis techneq failure;Residual renal function;

Countries

China

Contacts

Public ContactMa Xiaoyan

Shanghai East Hospital

yolosoco@163.com+86 21 3880 4518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026